Titre : Ureohydrolases

Ureohydrolases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Randomized Controlled Trials as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Ureohydrolases : Questions médicales les plus fréquentes", "headline": "Ureohydrolases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Ureohydrolases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-02", "dateModified": "2025-02-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Ureohydrolases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hydrolases", "url": "https://questionsmedicales.fr/mesh/D006867", "about": { "@type": "MedicalCondition", "name": "Hydrolases", "code": { "@type": "MedicalCode", "code": "D006867", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Arginase", "alternateName": "Arginase", "url": "https://questionsmedicales.fr/mesh/D001119", "about": { "@type": "MedicalCondition", "name": "Arginase", "code": { "@type": "MedicalCode", "code": "D001119", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.913.292" } } } ], "about": { "@type": "MedicalCondition", "name": "Ureohydrolases", "alternateName": "Ureohydrolases", "code": { "@type": "MedicalCode", "code": "D014512", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "M Sinn", "url": "https://questionsmedicales.fr/author/M%20Sinn", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Konstanz, Konstanz, Germany. malte.sinn@uni-konstanz.de." } }, { "@type": "Person", "name": "L Riede", "url": "https://questionsmedicales.fr/author/L%20Riede", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Konstanz, Konstanz, Germany." } }, { "@type": "Person", "name": "J R Fleming", "url": "https://questionsmedicales.fr/author/J%20R%20Fleming", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Konstanz, Konstanz, Germany." } }, { "@type": "Person", "name": "D Funck", "url": "https://questionsmedicales.fr/author/D%20Funck", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Konstanz, Konstanz, Germany." } }, { "@type": "Person", "name": "H Lutz", "url": "https://questionsmedicales.fr/author/H%20Lutz", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Konstanz, Konstanz, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A Mediterranean-Diet-Based Nutritional Intervention for Children with Prediabetes in a Rural Town: A Pilot Randomized Controlled Trial.", "datePublished": "2022-09-01", "url": "https://questionsmedicales.fr/article/36079871", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/nu14173614" } }, { "@type": "ScholarlyArticle", "name": "Ultrasound-guided paravertebral blockade reduced perioperative opioids requirement in pancreatic resection: A randomized controlled trial.", "datePublished": "2022-08-30", "url": "https://questionsmedicales.fr/article/36111230", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fsurg.2022.903441" } }, { "@type": "ScholarlyArticle", "name": "Pericapsular nerve group (PENG) block for hip arthroscopy: a randomized, double-blinded, placebo-controlled trial.", "datePublished": "2022-08-23", "url": "https://questionsmedicales.fr/article/35998937", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/rapm-2022-103907" } }, { "@type": "ScholarlyArticle", "name": "A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.", "datePublished": "2022-08-23", "url": "https://questionsmedicales.fr/article/36644237", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jhepr.2022.100563" } }, { "@type": "ScholarlyArticle", "name": "Chopstick technique versus cross technique in LESS hysterectomy (CCLEH study): a prospective randomized controlled trial.", "datePublished": "2022-08-20", "url": "https://questionsmedicales.fr/article/35987770", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13063-022-06650-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Hydrolases", "item": "https://questionsmedicales.fr/mesh/D006867" }, { "@type": "ListItem", "position": 5, "name": "Ureohydrolases", "item": "https://questionsmedicales.fr/mesh/D014512" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Ureohydrolases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Ureohydrolases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Ureohydrolases", "description": "Comment diagnostiquer une déficience en ureohydrolases ?\nQuels tests sont utilisés pour évaluer l'activité des ureohydrolases ?\nQuels symptômes indiquent un problème avec les ureohydrolases ?\nLes tests génétiques sont-ils utiles pour les ureohydrolases ?\nComment l'historique médical aide-t-il au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D014512?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Ureohydrolases", "description": "Quels sont les symptômes d'une accumulation d'urée ?\nComment se manifeste une hyperammoniémie ?\nLes symptômes varient-ils selon l'âge ?\nQuels signes cliniques sont associés à une déficience en ureohydrolases ?\nPeut-on avoir des symptômes sans déficience enzymatique ?", "url": "https://questionsmedicales.fr/mesh/D014512?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Ureohydrolases", "description": "Peut-on prévenir les troubles liés aux ureohydrolases ?\nLes conseils diététiques peuvent-ils prévenir ces troubles ?\nLe dépistage néonatal est-il recommandé ?\nLes antécédents familiaux influencent-ils la prévention ?\nLes vaccinations ont-elles un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D014512?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Ureohydrolases", "description": "Quel est le traitement principal pour les troubles liés aux ureohydrolases ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nLa dialyse est-elle une option de traitement ?\nLes thérapies nutritionnelles sont-elles efficaces ?\nY a-t-il des traitements expérimentaux pour ces troubles ?", "url": "https://questionsmedicales.fr/mesh/D014512?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Ureohydrolases", "description": "Quelles complications peuvent survenir avec une hyperammoniémie ?\nLes troubles du comportement sont-ils une complication ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nLes complications peuvent-elles survenir à tout âge ?", "url": "https://questionsmedicales.fr/mesh/D014512?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Ureohydrolases", "description": "Quels sont les facteurs de risque pour les troubles des ureohydrolases ?\nL'alimentation joue-t-elle un rôle dans les facteurs de risque ?\nLes infections peuvent-elles aggraver les troubles ?\nLes facteurs environnementaux influencent-ils ces troubles ?\nLes médicaments peuvent-ils être un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D014512?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en ureohydrolases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et urinaires mesurant les niveaux d'urée et d'ammoniac sont effectués." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des ureohydrolases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques spécifiques et des analyses biochimiques sont utilisés." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec les ureohydrolases ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la confusion, la fatigue et des troubles neurologiques peuvent apparaître." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les ureohydrolases ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent identifier des mutations génétiques liées à des déficiences enzymatiques." } }, { "@type": "Question", "name": "Comment l'historique médical aide-t-il au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical peut révéler des antécédents familiaux de troubles métaboliques." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une accumulation d'urée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des nausées, des vomissements, et des troubles de la conscience." } }, { "@type": "Question", "name": "Comment se manifeste une hyperammoniémie ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle se manifeste par des troubles neurologiques, des céphalées et des convulsions." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent être plus graves chez les nourrissons et les jeunes enfants." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à une déficience en ureohydrolases ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'irritabilité, la léthargie et des troubles de l'alimentation peuvent apparaître." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans déficience enzymatique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, d'autres conditions médicales peuvent provoquer des symptômes similaires." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés aux ureohydrolases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un dépistage précoce peut aider à gérer les risques." } }, { "@type": "Question", "name": "Les conseils diététiques peuvent-ils prévenir ces troubles ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conseils diététiques peuvent réduire le risque d'accumulation d'urée." } }, { "@type": "Question", "name": "Le dépistage néonatal est-il recommandé ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage néonatal peut identifier les troubles métaboliques précocement." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles peuvent justifier un suivi médical accru." } }, { "@type": "Question", "name": "Les vaccinations ont-elles un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Non, les vaccinations ne préviennent pas directement les troubles liés aux ureohydrolases." } }, { "@type": "Question", "name": "Quel est le traitement principal pour les troubles liés aux ureohydrolases ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est une restriction protéique et des suppléments d'arginine." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à gérer les symptômes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments peuvent être prescrits pour réduire les niveaux d'ammoniac." } }, { "@type": "Question", "name": "La dialyse est-elle une option de traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la dialyse peut être utilisée pour éliminer l'excès d'ammoniac dans les cas graves." } }, { "@type": "Question", "name": "Les thérapies nutritionnelles sont-elles efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une thérapie nutritionnelle adaptée peut aider à gérer les niveaux d'urée." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour ces troubles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements expérimentaux, comme la thérapie génique, sont en cours d'étude." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une hyperammoniémie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications graves incluent des lésions cérébrales et des troubles neurologiques." } }, { "@type": "Question", "name": "Les troubles du comportement sont-ils une complication ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles du comportement peuvent survenir en raison de l'accumulation d'ammoniac." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent gravement affecter la qualité de vie et nécessiter des soins constants." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Les complications peuvent-elles survenir à tout âge ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent survenir à tout âge, mais sont plus fréquentes chez les jeunes." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles des ureohydrolases ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des maladies métaboliques et des régimes inappropriés." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en protéines peut augmenter le risque d'accumulation d'urée." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver les troubles ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent exacerber les symptômes et augmenter les niveaux d'ammoniac." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils ces troubles ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux comme la pollution peuvent affecter le métabolisme." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils être un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent interférer avec le métabolisme de l'urée et des enzymes." } } ] } ] }

Sources (10000 au total)

Ultrasound-guided paravertebral blockade reduced perioperative opioids requirement in pancreatic resection: A randomized controlled trial.

Perioperative opioid use for pain control has been found to be associated with side effects and adverse prognosis. In this study, we hypothesized that paravertebral block could reduce the consumption ... We conducted a prospective, randomized trial. Patients with resectable pancreatic cancer were randomly assigned to one of the two groups: those who received bilateral paravertebral block combined with... A total of 153 patients were enrolled in the study and 119 cases were analyzed. Compared to the control group, patients in PTB patients had significantly lower perioperative (30.81 vs. 56.17 µg), and ... Bilateral paravertebral block combined with general anesthesia reduced the perioperative consumption of opioids by 45%.... ChiCTR1800020291 (available on http://www.chictr.org.cn/)....

Pericapsular nerve group (PENG) block for hip arthroscopy: a randomized, double-blinded, placebo-controlled trial.

Arthroscopic hip surgery is associated with significant postoperative pain. Femoral nerve blocks have been shown to improve postoperative analgesia at the expense of quadriceps weakness. The pericapsu... Subjects presenting for arthroscopic hip surgery were randomized in a 1:1 ratio to either an ultrasound-guided unilateral, single-injection PENG block (PENG group) with 20 mL of 0.5% ropivacaine or a ... Sixty-eight subjects, 34 from the PENG group and 34 from the Sham group, completed the study per protocol. Analysis of the primary outcome demonstrated a mean difference in pain scores of -0.79 (95% C... This study demonstrates that a preoperative PENG block does not improve analgesia following arthroscopic hip surgery.... NCT04508504....

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.

Efruxifermin has shown clinical efficacy in patients with non-alcoholic steatohepatitis (NASH) and F1-F3 fibrosis. The primary objective of the BALANCED Cohort C was to assess the safety and tolerabil... Patients with NASH and stage 4 fibrosis (n = 30) were randomized 2:1 to receive efruxifermin 50 mg (n = 20) or placebo (n = 10) once-weekly for 16 weeks. The primary endpoint was safety and tolerabili... Efruxifermin was safe and well-tolerated; most adverse events (AEs) were grade 1 (n = 7, 23.3%) or grade 2 (n = 19, 63.3%). The most frequent AEs were gastrointestinal, including transient, mild to mo... Efruxifermin appeared safe and well-tolerated with encouraging improvements in markers of liver injury, fibrosis, and glucose and lipid metabolism following 16 weeks of treatment, warranting confirmat... Cirrhosis resulting from non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease, represents a major unmet medical need. Currently there are no approved drugs f... NCT03976401....

Chopstick technique versus cross technique in LESS hysterectomy (CCLEH study): a prospective randomized controlled trial.

The traditional cross technique can be used to complete most laparoendoscopic single-site surgery (LESS) procedures, but some relatively precise operations, such as vaginal stump suturing, are challen... Patients who undergo total hysterectomy will be enrolled in this RCT. Stratified randomization will be performed according to uterine size (< 10 cm, 10-15cm, ≥ 15 cm). The participants will be divided... It is expected that the efficacy of the two techniques in LESS, the chopstick technique vs. the cross technique, will be compared and accumulate safety data on the new techniques will be accumulated.... ChiCTR2000040843, registered on June 16,2020 Protocol version: Version 2.0; Date: 2020.05.10....

Comparative Efficacy of Neuromodulation Technologies for Overactive Bladder in Adults: A Network Meta-Analysis of Randomized Controlled Trials.

The aim of this study was to investigate the comparative efficacy of neuromodulation technologies for overactive bladder (OAB) syndrome in adults.... A computerized search was conducted of Cochrane Library, EMBASE, MEDLINE (via PubMed), Web of Science, CNKI, Wan Fang Data, and ClinicalTrials.gov up to April 21, 2022.... The search selected clinical trials with random allocation to percutaneous tibial nerve stimulation (PTNS), transcutaneous tibial nerve stimulation (TTNS), vaginal electrical stimulation (VES), sacral... The main outcomes were the voiding diary, OAB-related quality of life, and positive response rate. The Cochrane Risk of Bias tool (RoB 2.0) was used to assess the risk of bias of each included study, ... The study included 21 randomized controlled trials involving 1433 participants, and all trials were used for the meta-analysis. In the network meta-analyses, five of six neuromodulation technologies, ... Neuromodulation technologies, including PTNS, TTNS, VES, SNM, and PS, may be effective and safe solutions for OAB syndrome in adults. Moreover, SNM is the most efficacious regimen for OAB-related qual...

Effects of side-effect risk framing strategies on COVID-19 vaccine intentions: a randomized controlled trial.

Fear over side-effects is one of the main drivers of COVID-19 vaccine hesitancy. A large literature in the behavioral and communication sciences finds that how risks are framed and presented to indivi... We conducted a pre-registered randomized controlled trial among 8998 participants in the United States and the United Kingdom to examine the effects of different ways of framing and presenting vaccine... Adding a descriptive risk label ('very low risk') next to the numerical side-effect and providing a comparison to motor-vehicle mortality increased participants' willingness to take the COVID-19 vacci... Low-cost side-effect framing strategies can meaningfully affect vaccine intentions at a population level.... Heidelberg Institute of Global Health.... German Clinical Trials Registry (#DRKS00025551)....

A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis.

To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA).... Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patients ≤ 18 years old with JoSpA not responding to nonsteroidal anti-inflammatory drugs, sulfasalazine, or met... We randomized 12 patients to infliximab and 14 to placebo. No significant differences were found between groups at baseline. At week 12, the mean number of active joints was 1.4 (SD 2.4) in the inflix... Infliximab is efficacious for patients with JoSpA with an inadequate response to conventional treatment. No serious adverse events with the use of infliximab were observed....